Abstract
BACKGROUND: Treatment resistant depression (TRD) has been identified as non-response to depression with adequate dose and trial of two antidepressant medications of different classes. Near about 30% depressive patients are TRD cases. Olanzapine-fluoxetine combination, rTMS, Intravenous ketamine and Electroconvulsive therapy have been till now studied in TRD. Dextromethorphan-bupropion is a newer antidepressant, which has been found to be effective, fast-acting, and well tolerated medicine for depression. CASES AND CONCLUSION: We used this novel antidepressant in three cases of TRD, alone and with combination, and it showed satisfactory response within 2 weeks.